Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine induced partial protection against clinical malaria in infants and children; given the high burden of the disease it is currently considered for use in malaria endemic countries. To inform adoption decisions the paper proposes a generalizable methodology to estimate the cost of vaccine introduction using routinely collected and publicly available data from the cMYP, UNICEF, and WHO-CHOICE. Costing is carried out around a set of generic activities, assumptions, and inputs for delivery of immunization services adapted to a given country and deployment modality to capture among other factors the structure of the EPI program, distribution model, geography,...
Background: The RTS,S/AS01 E malaria vaccine is being assessed in Malawi, Ghana and Kenya as part of...
Purpose This study provides a systematic literature review and categorization of the costs reported ...
BACKGROUND: RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in...
AbstractRecent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine in...
Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine induced pa...
Abstract Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccin...
AbstractRecent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine in...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in endemic Afr...
BackgroundThe RTS,S/ASO1E malaria vaccine is being piloted in three countries-Ghana, Kenya, and Mala...
AbstractBackgroundRTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementat...
Background. The World Health Organization is planning a pilot introduction of a new malaria vaccine ...
AbstractBackgroundRTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementat...
Background: The RTS,S/AS01 E malaria vaccine is being assessed in Malawi, Ghana and Kenya as part of...
Purpose This study provides a systematic literature review and categorization of the costs reported ...
BACKGROUND: RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in...
AbstractRecent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine in...
Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine induced pa...
Abstract Recent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccin...
AbstractRecent results from the phase 3 trial of RTS,S/AS01 malaria vaccine show that the vaccine in...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
Background. The World Health Organization has recommended pilot implementation of a candidate vaccin...
RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in endemic Afr...
BackgroundThe RTS,S/ASO1E malaria vaccine is being piloted in three countries-Ghana, Kenya, and Mala...
AbstractBackgroundRTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementat...
Background. The World Health Organization is planning a pilot introduction of a new malaria vaccine ...
AbstractBackgroundRTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementat...
Background: The RTS,S/AS01 E malaria vaccine is being assessed in Malawi, Ghana and Kenya as part of...
Purpose This study provides a systematic literature review and categorization of the costs reported ...
BACKGROUND: RTS,S/AS01 is a safe and moderately efficacious vaccine considered for implementation in...